Style | Citing Format |
---|---|
MLA | Shahrestanaki MK, Aghaei M. "A3 Receptor Agonist, Cl-Ibmeca, Potentiate Glucose-Induced Insulin Secretion From Min6 Insulinoma Cells Possibly Through Transient Ca2+ Entry." Research in Pharmaceutical Sciences, vol. 14, no. 2, 2019, pp. 107-114. |
APA | Shahrestanaki MK, Aghaei M (2019). A3 Receptor Agonist, Cl-Ibmeca, Potentiate Glucose-Induced Insulin Secretion From Min6 Insulinoma Cells Possibly Through Transient Ca2+ Entry. Research in Pharmaceutical Sciences, 14(2), 107-114. |
Chicago | Shahrestanaki MK, Aghaei M. "A3 Receptor Agonist, Cl-Ibmeca, Potentiate Glucose-Induced Insulin Secretion From Min6 Insulinoma Cells Possibly Through Transient Ca2+ Entry." Research in Pharmaceutical Sciences 14, no. 2 (2019): 107-114. |
Harvard | Shahrestanaki MK, Aghaei M (2019) 'A3 Receptor Agonist, Cl-Ibmeca, Potentiate Glucose-Induced Insulin Secretion From Min6 Insulinoma Cells Possibly Through Transient Ca2+ Entry', Research in Pharmaceutical Sciences, 14(2), pp. 107-114. |
Vancouver | Shahrestanaki MK, Aghaei M. A3 Receptor Agonist, Cl-Ibmeca, Potentiate Glucose-Induced Insulin Secretion From Min6 Insulinoma Cells Possibly Through Transient Ca2+ Entry. Research in Pharmaceutical Sciences. 2019;14(2):107-114. |
BibTex | @article{ author = {Shahrestanaki MK and Aghaei M}, title = {A3 Receptor Agonist, Cl-Ibmeca, Potentiate Glucose-Induced Insulin Secretion From Min6 Insulinoma Cells Possibly Through Transient Ca2+ Entry}, journal = {Research in Pharmaceutical Sciences}, volume = {14}, number = {2}, pages = {107-114}, year = {2019} } |
RIS | TY - JOUR AU - Shahrestanaki MK AU - Aghaei M TI - A3 Receptor Agonist, Cl-Ibmeca, Potentiate Glucose-Induced Insulin Secretion From Min6 Insulinoma Cells Possibly Through Transient Ca2+ Entry JO - Research in Pharmaceutical Sciences VL - 14 IS - 2 SP - 107 EP - 114 PY - 2019 ER - |